Chugai announces launch of the anti-cancer agent “Kadcyla” in Japan
Chugai announced it will launch the anti-HER2 antibody-tubulin polymerization inhibitor conjugate “Kadcyla® Intravenous Infusion
100 mg and 160 mg” [generic name: Kadcyla®) for the indication of “HER2-positive inoperable or recurrent breast cancer.” April 17, 2014